ライフサイエンスコーパス: gadopentetate dimeglumine

1 <.05 for Gadomer-17 and r = 0.80, P <.05 for gadopentetate dimeglumine).

2 001 for Gadomer-17 and r = 0.75, P <.001 for gadopentetate dimeglumine).

3 aseline and after a 30-40-minute infusion of gadopentetate dimeglumine.

4 aging before and after the administration of gadopentetate dimeglumine.

5 (GRE) imaging before and after injection of gadopentetate dimeglumine.

6 ho times after intravenous administration of gadopentetate dimeglumine.

7 ts after administration of a single bolus of gadopentetate dimeglumine.

8 isitions before and during administration of gadopentetate dimeglumine.

9 rmed after the administration of 0.2 mmol/kg gadopentetate dimeglumine.

10 sion after the administration of 0.2 mmol/kg gadopentetate dimeglumine.

11 after injection of a 0.5-mL timing bolus of gadopentetate dimeglumine.

12 r gadobenate dimeglumine was substituted for gadopentetate dimeglumine.

13 with separate doses of 0.075 and 0.1 mmol/kg gadopentetate dimeglumine.

14 sequence before and after administration of gadopentetate dimeglumine.

15 examinations) during infusion of 0.2 mmol/kg gadopentetate dimeglumine.

16 ormed in two phases with saline and 2 mmol/L gadopentetate dimeglumine.

17 rom the original baseline reaction rate with gadopentetate dimeglumine.

18 specimens (eight joints), after injection of gadopentetate dimeglumine.

19 patients after administration of 0.1 mmol/kg gadopentetate dimeglumine.

20 P < .0001) allergic-like reactions than was gadopentetate dimeglumine.

21 and contrast material-enhanced imaging with gadopentetate dimeglumine.

22 compared with the kinetics of di-tyrosine of gadopentetate dimeglumine.

23 years) after dynamic injection of 8-10 mL of gadopentetate dimeglumine.

24 volume (DV), and mean transit time (MTT) of gadopentetate dimeglumine.

25 phases after intravenous bolus injection of gadopentetate dimeglumine.

26 eglumine compared with that with 0.1 mmol/kg gadopentetate dimeglumine.

27 were acquired before and after injection of gadopentetate dimeglumine.

28 tion of a low dose (2 mL or 0.01 mmol/kg) of gadopentetate dimeglumine.

29 chemic from remote myocardium than that with gadopentetate dimeglumine.

30 formed during a dual-bolus administration of gadopentetate dimeglumine (0.0025 mmol/kg followed by 0.

31 performed before and after administration of gadopentetate dimeglumine (0.1 mmol per kilogram of body

32 f an MPO-specific (di-5-hydroxytryptamide of gadopentetate dimeglumine, 0.1 mmol per kilogram of body

33 eight) or a non-MPO-specific (di-tyrosine of gadopentetate dimeglumine, 0.1 mmol/kg) contrast agent,

34 All animals received gadopentetate dimeglumine 1 hour after reperfusion and u

35 jections of gadolinium-based contrast media (gadopentetate dimeglumine, 31 540; gadobenate dimeglumin

36 r gadobenate dimeglumine was substituted for gadopentetate dimeglumine, a significant transient incre

37 in 207 consecutive patients before and after gadopentetate dimeglumine administration.

38 ssue enhancement are affected by the rate of gadopentetate dimeglumine administration.

39 rmed by using different IRE parameters after gadopentetate dimeglumine administration.

40 -of-flight (TOF) MR imaging before and after gadopentetate dimeglumine administration.

41 Liposomes encapsulating gadopentetate dimeglumine, an MR-detectable model repres

42 than in normal myocardium (0.23 +/- 0.02 for gadopentetate dimeglumine and 0.16 +/- 0.01 for 99mTc-DT

43 mol per kilogram of body weight of 0.5 mol/L gadopentetate dimeglumine and 0.5 mol/L gadobenate dimeg

44 r in infarcted myocardium (0.90 +/- 0.05 for gadopentetate dimeglumine and 0.89 +/- 0.04 for 99mTc-DT

45 The fractional distribution volumes of gadopentetate dimeglumine and 99mTc-DTPA are similar and

46 acquired up to 10, 30, and 50 minutes after gadopentetate dimeglumine and both gadomer-17 injections

47 and the remaining rat was administered both gadopentetate dimeglumine and cationized ferritin to vis

48 s, after administration of mesoporphyrin and gadopentetate dimeglumine and histochemical staining, th

49 emained at baseline in NASH mice imaged with gadopentetate dimeglumine and in MPO knockout NASH mice

50 tients) received intraarticular injection of gadopentetate dimeglumine and normal saline in a ratio o

51 assess the relationship between the dose of gadopentetate dimeglumine and the time to onset of NSF.

52 ptibility artifact was threefold dilution of gadopentetate dimeglumine and use of a short echo time (

53 <.05 for Gadomer-17 and r = 0.60, P =.05 for gadopentetate dimeglumine) and with areas of reduced MBF

54 ntrast agents (gadodiamide, gadoversetamide, gadopentetate dimeglumine, and gadobenate dimeglumine) p

55 st to the more general enhancement seen with gadopentetate dimeglumine, and reflux from the duodenum

56 om gadodiamide to gadobenate dimeglumine and gadopentetate dimeglumine, and the adoption of restricti

57 al veins after intravenous administration of gadopentetate dimeglumine, and these data were used to c

58 hyrin at 2 hours, the other 16 rats received gadopentetate dimeglumine at 24 hours, and all animals u

59 de, gadobenate dimeglumine, gadodiamide, and gadopentetate dimeglumine at a concentration of 0.1 mmol

60 ram was obtained after the administration of gadopentetate dimeglumine at a concentration of 25% with

61 adobenate dimeglumine compared with that for gadopentetate dimeglumine at all time points from 3 minu

62 er-17 was 20% (P <.05) higher than that with gadopentetate dimeglumine at first-pass imaging.

63 ormed in 60 patients after administration of gadopentetate dimeglumine (average dose, 0.11 mmol/kg).

64 sed by serial application of the linear GBCA gadopentetate dimeglumine but not by the macrocyclic GBC

65 que during the administration of 0.1 mmol/kg gadopentetate dimeglumine by means of bolus (10-second)

66 d a guide wire was filled with a solution of gadopentetate dimeglumine, catheter movement was always

67 with MPO-Gd and vasculitis mice imaged with gadopentetate dimeglumine (CNR = 10.6) (P < .05).

68 w product data normalized to pectoral muscle gadopentetate dimeglumine concentration in invasive canc

69 The T1 values, change in gadopentetate dimeglumine concentration, and extraction-

70 (30%) of 54 patients with prior exposure to gadopentetate dimeglumine contrast during imaging studie

71 Gadopentetate dimeglumine did not produce selective enha

72 regions displayed by using mesoporphyrin and gadopentetate dimeglumine differed from each other.

73 Gadopentetate dimeglumine diluted 1:1 with 0.9% normal s

74 nts who received higher cumulative and total gadopentetate dimeglumine doses had a higher risk of dev

75 eceived low-dose (approximately 0.1 mmol/kg) gadopentetate dimeglumine during a three-station, dual-i

76 Hyperintensity from gadopentetate dimeglumine enabled visualization of renal

77 quences and 3D TOF sequences with or without gadopentetate dimeglumine enables accurate identificatio

78 ons and one in 44,224 patients who underwent gadopentetate dimeglumine-enhanced MR examinations.

79 imensional fat-saturated T1-weighted dynamic gadopentetate dimeglumine-enhanced sequences also were p

80 nflamed aneurysms, di-5-hydroxytryptamide of gadopentetate dimeglumine exhibited delayed washout kine

81 NSF developed within 3 months after the last gadopentetate dimeglumine exposure (range, 1-59 months)

82 Medical records were then reviewed for gadopentetate dimeglumine exposure, renal status, concom

83 ations included pre- and postcontrast (20 mL gadopentetate dimeglumine) fat-saturated 2D GRE breath-h

84 mors correlated well with those observed for gadopentetate dimeglumine (Fe-tCDTA Pearson R, 0.99; P =

85 in three cadaveric knees, with placement of gadopentetate dimeglumine-filled tubes along their cours

86 andomly assigned to receive either MPO-Gd or gadopentetate dimeglumine first.

87 nd more persistent CNR improvements than did gadopentetate dimeglumine; further evaluation of its uti

88 rations of three gadolinium contrast agents (gadopentetate dimeglumine, gadobenate dimeglumine, and g

89 2-cyclohexenediaminetriacetate (Mn-PyC3A) to gadopentetate dimeglumine (Gd-DTPA) and to evaluate the

90 The use of gadopentetate dimeglumine (Gd-DTPA) as a contrast agent

91 Gadopentetate dimeglumine (Gd-DTPA) dynamic magnetic res

92 hy was also performed with 5 mL of undiluted gadopentetate dimeglumine hand injected into each renal

93 The use of gadopentetate dimeglumine improved delineation of soft-t

94 nography after intrathecal administration of gadopentetate dimeglumine in 15 patients clinically susp

95 ents with renal impairment after exposure to gadopentetate dimeglumine in a dose- and time-dependent

96 the two chelates were compared with those of gadopentetate dimeglumine in blood serum phantoms at 1.5

97 Normal-saline bags containing gadopentetate dimeglumine in concentrations of 0-20 mmol

98 in images acquired during the first pass of gadopentetate dimeglumine in coronary arteries and up to

99 33 to be significantly longer than those for gadopentetate dimeglumine in regions of postinfarction s

100 es) and after the application of 0.2 mmol/kg gadopentetate dimeglumine in the interventricular septum

101 ignificantly higher for gadoteridol than for gadopentetate dimeglumine in the physis, epiphyseal cart

102 Inclusion of phantoms of gadopentetate dimeglumine in tubes allowed estimation of

103 determine the minimally efficacious dose of gadopentetate dimeglumine injection (Magnevist Injection

104 (n = 2) underwent IRE ablation without prior gadopentetate dimeglumine injection to serve as control

105 igher than that on the images obtained after gadopentetate dimeglumine injection.

106 ted three-dimensional gradient-echo MR after gadopentetate dimeglumine injection.

107 echo-planar pulse sequences before and after gadopentetate dimeglumine injection.

108 ty-five patients (nine who had received GBCA gadopentetate dimeglumine injections previously [one to

109 oteridol (nonionic contrast agent; n = 6) or gadopentetate dimeglumine (ionic contrast agent; n = 6).

110 Gadopentetate dimeglumine is an alternative radiographic

111 A low dose of 0.05 mmol/kg gadopentetate dimeglumine is at least as efficacious as

112 ymphangiography with intranodal injection of gadopentetate dimeglumine is feasible, produces good ima

113 Gadopentetate dimeglumine is of limited use.

114 a reduction in contrast-enhancing lesions on gadopentetate dimeglumine magnetic resonance images afte

115 of 4237]) in the 2nd year after it replaced gadopentetate dimeglumine (maximum per quarter, 0.10% [f

116 anced region demarcated by mesoporphyrin and gadopentetate dimeglumine may provide an estimation of p

117 e (MR) perfusion imaging with Gadomer-17 and gadopentetate dimeglumine, microsphere blood flow (MBF)

118 ibution of injected contrast agent solution (gadopentetate dimeglumine mixed with trypan blue dye) in

119 ted SE with intraarticular administration of gadopentetate dimeglumine (MR arthrography).

120 olinium) (n = 23), referred to as MPO-Gd, or gadopentetate dimeglumine (n = 10).

121 y identified and verified qualitatively with gadopentetate dimeglumine on both perfusion and BOLD ima

122 1 and DCE MR imaging in the same tumors with gadopentetate dimeglumine on day 2.

123 s) after the intravenous injection of either gadopentetate dimeglumine or EP-3533.

124 During intravenous bolus injection of gadopentetate dimeglumine or gadoteridol (0.1 mmol/kg),

125 h the exclusive use of either a linear GBCA (gadopentetate dimeglumine) or a macrocyclic GBCA (gadote

126 imaging after three injections: 0.20 mmol of gadopentetate dimeglumine per kilogram of body weight an

127 ter administration of a bolus of 0.1 mmol of gadopentetate dimeglumine per kilogram of body weight.

128 echniques with administration of 0.2 mmol of gadopentetate dimeglumine per kilogram of body weight.

129 es were obtained after injection of 0.1 mmol gadopentetate dimeglumine per kilogram of body weight.

130 ars; range, 30-83 years) had been exposed to gadopentetate dimeglumine prior to NSF onset.

131 Extracellular gadopentetate dimeglumine provided excellent infarct det

132 ble only until 55 seconds after injection of gadopentetate dimeglumine (PSIC, 36% +/- 24 vs 56% +/- 2

133 ] vs 100% +/- 32, respectively; P <.001) and gadopentetate dimeglumine (PSIC, 49% +/- 31 vs 81% +/- 4

134 lower, respectively, compared with those of gadopentetate dimeglumine (r1 = 4.1 mmol(-1) .

135 d in greater visibility of the physis, while gadopentetate dimeglumine resulted in greater contrast b

136 MR imaging with di-5-hydroxytryptamide of gadopentetate dimeglumine revealed a difference in enhan

137 tients) received intraarticular injection of gadopentetate dimeglumine, ropivacaine 0.5%, and normal

138 mmercially available catheters filled with a gadopentetate dimeglumine solution and a fast, two-dimen

139 rformed in 29 patients by using a first-pass gadopentetate dimeglumine T2*-weighted echo-planar perfu

140 Among these rats, two were administered gadopentetate dimeglumine to visualize renal tubules on

141 t in more precise quantitative estimation of gadopentetate dimeglumine uptake in breast tumors, which

142 tients had been exposed to median cumulative gadopentetate dimeglumine volumes of 35, 40, 85, and 117

143 h suspected renal artery stenosis, undiluted gadopentetate dimeglumine was administered in an aortic

144 Renal extraction fraction of gadopentetate dimeglumine was determined with T1 measure

145 The radiographic attenuation of the diluted gadopentetate dimeglumine was equivalent to diatrizoate

146 In the timing examination, 1 mL gadopentetate dimeglumine was followed with 15 mL saline

147 lumbar puncture, a single dose of 0.5 mL of gadopentetate dimeglumine was injected into the lumbar s

148 For comparison, gadopentetate dimeglumine was injected into three other

149 ) preference for gadobenate dimeglumine over gadopentetate dimeglumine was noted both off-site and on

150 led echo MR sequence after administration of gadopentetate dimeglumine was obtained.

151 maging with intraarticular administration of gadopentetate dimeglumine was performed in 10 adult cada

152 Gadopentetate dimeglumine was peripherally injected at r

153 ne was preferred in 13, 17, and 16 patients; gadopentetate dimeglumine was preferred in four, four, a

154 ional MR angiography performed with 30 mL of gadopentetate dimeglumine was the reference standard.

155 nter A) and Emory University (center B), and gadopentetate dimeglumine was used at Wake Forest Univer

156 amide was used than at the two centers where gadopentetate dimeglumine was used.

157 Intraarterial injections of small doses of gadopentetate dimeglumine were combined with a fast spoi

158 gadolinium-based contrast agents other than gadopentetate dimeglumine were excluded.

159 d early and late after the administration of gadopentetate dimeglumine were retrospectively evaluated

160 Gadobenate dimeglumine and gadopentetate dimeglumine were the agents used in the po

161 dixanol and 81 who underwent MR imaging with gadopentetate dimeglumine) were identified.

162 MR contrast agent di-5-hydroxytryptamide of gadopentetate dimeglumine, which is a paramagnetic MPO s

163 ) following intravenous injection of 2 mL of gadopentetate dimeglumine, which was repeated following

164 fore and dynamically after administration of gadopentetate dimeglumine, with the first enhanced acqui